


Access Oxford Biomedica's proven platform to rapidly bring your lentiviral vector (LV) therapy to market



#### Unique process development expertise

- Perfusion process (Process C)
- 50L and 200L suspension fedbatch process (Process B)
- Chemical and mRNA enhancers
- Automated product-specific DOE

### **Established analytics**

- Analytical methods accepted by regulatory authorities
- Routine development of new analytical methods
- Automated systems increasing efficiency and robustness

#### **Proprietary vectors**

- TetraVecta™ system potential to improve quality, potency and capacity with additional safety features
- Minimal 3<sup>rd</sup> generation LV system

## What makes our LentiVector® platform unique?

## 320+

320+ GMP batches successfully released in the past 10 years



#### Track record

- ✓ 25+ years of manufacturing experience (GMP manufacturing since 2014)
- √ Validated commercial platform
- ✓ Availability of Drug Masterfile with the FDA

## 1.9E+12<sub>TU</sub>

Vector product generated for therapeutic gene at 200L scale



#### **Performance**

 Recognised as leading platform by emerging biotechs and pharma companies

## 9-fold

Titre improvement achieved for a LV-CAR product with OXB technologies



#### **Innovation**

 Technologies and process upgrades to improve vector titre, quality, potency, safety, consistency of manufacturing, and scalability

## 12-months

Fastest timeline achieved from client onboarding to released GMP batch



#### Fast to GMP

√ Rapid entry to clinical trials without the need for tech transfer and process changes

## 40+

Number of countries with a commercially approved product using Oxford Biomedica LV



#### Widely adopted

- ✓ Our LV are used with multiple programmes across all development stages
- ✓ Trusted by broad range of customers from emerging biotech to large pharmaceutical companies

## 8,000+

Number of patients treated using Oxford Biomedica's LV



#### **Customer focus**

- ✓ Ability to tech transfer the LentiVector® platform to your facilities
- √ Strong focus on project management and communication

## LentiVector®

We are a quality and innovation-led CDMO with over 25 years of experience, committed to helping our clients deliver cell and gene therapies that transform patients' lives.

We offer end-to-end capabilities, from plasmid design and optimisation, to clinical and commercial GMP manufacturing, accompanied by robust control systems, analytical methods and deep regulatory knowledge.

# Let's do something life-changing together



For more information please contact:

Oxford Biomedica +44 (0) 1865 783 000 www.oxb.com

partnering@oxb.com

